BLOCKADE OF BCL-2 PROTEINS EFFICIENTLY INDUCES APOPTOSIS IN PROGENITOR CELLS OF HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS

被引：1
|
作者：
Jilg, S. [1 ]
Reidel, V. [1 ]
Mueller-Thomas, C. [1 ]
Koenig, J. [1 ]
Schauwecker, J. [2 ]
Burgkart, R. [2 ]
Hoeckendorf, U. [1 ]
Huberle, C. [1 ]
Gorka, O. [3 ]
Ruland, J. [3 ]
Kolb, H. [1 ]
Peschel, C. [1 ]
Oostendorp, R. [1 ]
Goetze, K. [1 ]
Jost, P. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 3, D-80290 Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Dept Orthoped, D-80290 Munich, Germany
[3] Tech Univ Munich, Klinikum Rechts Isar, Dept Clin Chem, D-80290 Munich, Germany
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30028-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
27
引用
收藏
页码：S12 / S12
页数：1
相关论文
共 50 条
  • [1] Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
    S Jilg
    V Reidel
    C Müller-Thomas
    J König
    J Schauwecker
    U Höckendorf
    C Huberle
    O Gorka
    B Schmidt
    R Burgkart
    J Ruland
    H-J Kolb
    C Peschel
    R A J Oostendorp
    K S Götze
    P J Jost
    Leukemia, 2016, 30 : 112 - 123
  • [2] Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients
    Jilg, S.
    Reidel, V.
    Mueller-Thomas, C.
    Koenig, J.
    Schauwecker, J.
    Hoeckendorf, U.
    Huberle, C.
    Gorka, O.
    Schmidt, B.
    Burgkart, R.
    Ruland, J.
    Kolb, H-J
    Peschel, C.
    Oostendorp, R. A. J.
    Goetze, K. S.
    Jost, P. J.
    LEUKEMIA, 2016, 30 (01) : 112 - 123
  • [3] Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)
    Fenaux, P
    SEMINARS IN ONCOLOGY, 2005, 32 (04) : S11 - S15
  • [4] Expression and prognostic significance of Bcl-2 family proteins in Myelodysplastic syndromes
    Boudard, D
    Vasselon, C
    Berthéas, MF
    Jaubert, J
    Mounier, C
    Reynaud, J
    Viallet, A
    Chautard, S
    Guyotat, D
    Campos, L
    AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (02) : 115 - 125
  • [5] Treatment of patients with high-risk myelodysplastic syndromes
    Gattermann, Norbert
    Kuendgen, Andrea
    Germing, Ulrich
    CANCER TREATMENT REVIEWS, 2007, 33 : S64 - S68
  • [6] The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
    Reinhard Stauder
    Annals of Hematology, 2012, 91 : 1333 - 1343
  • [7] The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
    Stauder, Reinhard
    ANNALS OF HEMATOLOGY, 2012, 91 (09) : 1333 - 1343
  • [8] Autologous peripheral blood progenitor cell transplantation in patients with high-risk myelodysplastic syndromes
    Verhoef, GEG
    Demuynck, H
    Delforge, M
    Vandenberghe, P
    Maertens, J
    Zachee, P
    Boogaerts, M
    PATHOLOGIE BIOLOGIE, 1997, 45 (08): : 651 - 655
  • [9] The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS
    Parker, JE
    Mufti, GJ
    Rasool, F
    Mijovic, A
    Devereux, S
    Pagliuca, A
    BLOOD, 2000, 96 (12) : 3932 - 3938
  • [10] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
12345